The Alzheimer's Drug Discovery Foundation

Novo Nordisk’s ‘lottery ticket’: can obesity drugs help treat Alzheimer’s? Results are due soon from two studies using semaglutide to treat thousands of people with the disease

Can GLP-1s also combat Alzheimer’s? Novo Nordisk’s EVOKE trial results will be presented at CTAD, building on ADDF-funded research by Dr. Paul Edison on liraglutide. Repurposed drugs & precision medicine could redefine how we treat #Alzheimer’s. on.ft.com/3J1HpTU

The World Dementia Council is hosting a virtual event on “Lessons from innovators: biomarkers.” Supported by @theaddf.bsky.social, this dialogue will explore rapid advances & key challenges in developing new dementia diagnostics. More here: bit.ly/4kUT4Re

FDA clears blood test to help rule out Alzheimer’s disease in people showing symptoms | CNN The US Food and Drug Administration has given clearance to another blood test to help assess Alzheimer’s disease and other causes of cognitive decline, providing a broader understanding of when the di...

Alzheimer’s care is evolving. The FDA clearance of Roche and @elilillyandcompany.bsky.social Elecsys pTau181 blood test marks a major step toward accessible, scalable diagnostics that bring detection into everyday clinical care. @cnn.com

Eisai and Biogen Leqembi Iqlik: The Best Inventions of 2025 Find out why Eisai and Biogen Leqembi Iqlik is on TIME's list of 2025's best inventions.

We’re proud to celebrate Eisai and Biogen for Leqembi Iqlik being named one of TIME's Best Inventions of 2025. This marks incredible innovation in Alzheimer’s care, paving the way for faster & simpler delivery that can be self-administered at home like GLP-1s. bit.ly/4q9P976

Meet 20 women reshaping biopharma, from early discovery to patient advocacy A project highlighting women in biopharma has grown since 2019, now honoring over 140 women who've shaped the industry through work on rare diseases, IPOs, AI drug discovery and patient advocacy. Desp...

Congratulations to our friend and partner Anne White, who has been named one of Endpoints News’ Women in Biopharma 2025. Anne’s impact and leadership at @elilillyandcompany.bsky.social from advancing oncology to Alzheimer’s breakthroughs continues to transform the field.

bit.ly/3INh5wG

The way we talk about dementia is about to change completely “The more we talk, debate, even sometimes argue, the more we can live well with a mind altered by these progressive, disabling brain diseases,” Jason Karlawish writes.

The conversation around Alzheimer’s care is shifting. Dr. Jason Karlawish explores how advances in disease-modifying therapies and novel diagnostics are transforming society at large—a future defined by combination therapy and precision medicine. bit.ly/3KD9IIx

Today, our partners C2N Diagnostics submitted the #PrecivityAD2 blood test to the #FDA for approval, enabling earlier diagnosis and intervention for Alzheimer's treatment, a core tenet of the ADDF's DxA. The next frontier is precision medicine. bit.ly/46Lw4yV

The ADDF’s DxA announced two milestones: the release of #SpeechDx’s first data tranche & a new partnership with
Callyope. This gold-standard dataset will power a new generation of #AI tools to detect, diagnose, monitor, and even treat Alzheimer’s.

bit.ly/4ohctOz

YouTube video by Alzheimer's Drug Discovery Foundation Meet the Minds Behind the Mission: A Q&A with ADDF Scientists

Missed our latest webinar? Tune in to an extraordinary conversation with the ADDF’s scientific leaders, Aaron Burstein, PharmD, and Melissa Lee, PhD, as they discuss the cutting-edge #Alzheimer’s research in 2025, fueled by the ADDF’s bold vision.
www.youtube.com/watch?v=I_XO...

The European Commission has authorized #Kisunla, marking a new era in #Alzheimer's treatment and accelerating global innovation. This milestone expands access for patients and families, enabling early detection and treatments that help slow decline. @elilillyandcompany.bsky.social
bit.ly/46mYY9M

New landscape of the diagnosis of Alzheimer's disease Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individu...

Alzheimer’s is undergoing a diagnostic revolution. A new series from The Lancet explores how advances in biomarkers are transforming diagnosis, enabling more equitable and affordable access to treatment, which speaks to the DxA’s mission.

bit.ly/4pFkVID

Doctors Are Torn over Controversial New Alzheimer’s Treatments. Here’s Why New Alzheimer’s drugs known as anti-amyloid therapies may slow disease progression—but they also carry serious risks, including brain bleeds and strokelike symptoms

A new era of Alzheimer's treatment is here. Dr. Fillit shares with
@sciam.bsky.social that the future lies in precision combination therapies, like in cancer. The path forward will combine anti-amyloid and tau therapies with novel treatments that target the biology of aging, such as inflammation.

What if we could stop Alzheimer’s before it starts? Imagine knowing years in advance who will develop Alzheimer’s and when. Imagine being able to use that time to act – deploying targeted drugs and lifestyle interventions to prevent the disease from ev...

With advances in #AI-powered tools, Melissa Lee, PhD, highlights the ADDF’s Diagnostics Accelerator vision: a future where blood tests, speech samples, and digital tools enable early detection and personalized care for #Alzheimer’s.

www.linkedin.com/pulse/what-w...

Navigating the Alzheimer Disease Blood Test Revolution A new FDA-approved blood test for Alzheimer disease could transform diagnosis and treatment accessibility, according to this conversation with Howard Fillit, MD, and Anthony “Nino” Sireci, MD, MSc.

On the latest episode of Managed Care Cast, Dr. Fillit and Dr. Anthony Sireci, @elilillyandcompany.bsky.social, discuss a transformative milestone in Alzheimer’s care: the first-ever FDA clearance for a blood test, the Lumipulse plasma assay. bit.ly/47GLnv8

https://www.pbs.org/show/healthy-minds-with-dr-jeffrey-borenstein/

Alzheimer’s Disease: Diagnosis & Treatment: Blood tests that show biomarkers for Alzheimer’s disease can delay onset of symptoms.
.
Learn more here: bbrfoundation.org/healthy-mind...
.
@theaddf.bsky.social @pbs.org #mentalhealth

Novo Has High Hopes That Ozempic Pill Can Also Fight Dementia From obesity and diabetes to heart and liver disease, the applications for GLP-1 drugs have multiplied since Ozempic arrived on the scene seven years ago. Now, Novo is testing their effect on Alzheime...

#GLP-1s have the potential to redefine #Alzheimer's treatment. @a_hfillit shared with #Bloomberg that #semaglutide could become “one of the first anti-aging drugs,” bringing Alzheimer’s care closer to combination therapies & precision medicine, like in cancer. bloom.bg/4nipzdO

Today marks a great step forward with the first-ever #FDA approval of the subcutaneous formulation of #Leqembi (lecanemab), a major advancement ushering in the next gen of #Alzheimer’s care with combination therapy and precision medicine.
bit.ly/47Pga8Y

Is Venture Philanthropy Right for Your Startup? Here’s How to Tell At a time when federal funding is shrinking, healthcare startups are finding critical support from mission-driven venture philanthropies like the ADDF and LLS willing to back early-stage, high-risk sc...

Healthcare startups are turning to venture philanthropy to advance bold ideas amid a challenging funding environment. Karen Harris shares how the ADDF bridges the gap with investments and a willingness to support high-risk, early-stage science.
wewillcure.com/insights/inv...

Lecanemab Preserves Memory Over 4 Years in Early AD Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

New 4-year CLARITY AD data show #lecanemab slows decline & improves function in #Alzheimer’s. Dr. Howard Fillit tells Medscape this is a major advancement in reducing progression risk by 34%. This data brings us closer to #precision #medicine in Alzheimer’s care.
wb.md/3H2BUn0